✦ LIBER ✦

Tetrabenazine as a cause of neuroleptic malignant syndrome

✍ Scribed by M. Ossemann; C. J. M. Sindic; C. Laterre

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 129 KB
Volume: 11
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870110118

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A case of tetrabenazine-induced neurolep

A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment

✍ Giselle M. Petzinger; Susan B. Bressman 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB

We report the case of a patient with tardive dystonia and a history of psychiatric illness who showed signs of neuroleptic malignant syndrome (NMS) after chronic treatment with tetrabenazine. The first symptom was a mental status change 'consisting of confusion, disorganized thinking, paranoid delus

Hyperglycemia as a symptom of neurolepti

Hyperglycemia as a symptom of neuroleptic malignant syndrome

✍ M. Ishida; K. Otani; S. Kaneko; H. Ishida; S. Kawashima 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

A 67-year-old schizophrenic woman developed neuroleptic malignant syndrome (NMS). She had mild diabetes mellitus, which had been controlled with diet therapy only. Upon the onset of NMS, hyperglycemia of up to 490 mg/dl developed. The hyperglycemia persisted during the NMS episode despite insulin tr

Paralytic ileus as a prodromal symptom o

Paralytic ileus as a prodromal symptom of the neuroleptic malignant syndrome

✍ Osamu Tanaka; Koichi Otani; Tsuyoshi Kondo; Sunao Kaneko; Yutaka Fukushima 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

## Abstract A schizophrenic patient receiving neuroleptic treatment developed paralytic ileus followed by the neuroleptic malignant syndrome (NMS). The patient had previously experienced two NMS episodes, one of which was also accompanied by paralytic ileus. It is suggested that paralytic ileus can

Neoplasia and the neuroleptic malignant

Neoplasia and the neuroleptic malignant syndrome

✍ P. W. R. Wooduff; E. Palazidou; I. Cranston; B. K. Toone; B. Summers; A. L. W. F 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

## Abstract The association of neuroleptic malignant syndrome with neoplasia has not been previously reported. We report the case of a 64‐year‐old female patient who developed the classical picture of neuroleptic malignant syndrome in relation to a uterine leiomyosarcoma. This raises the question a

Treatment of neuroleptic malignant syndr

Treatment of neuroleptic malignant syndrome with levodopa

✍ K. Otani; K. Mihara; T. Kondo; M. Okada; S. Kaneko; Y. Fukushima 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB

Seven consecutive episodes of neuroleptic malignant syndrome in five cases were treated with 50-600 mg/day (mean 342 mg/day) of levodopa. In four episodes active pharmacological treatment was initiated with levodopa, while in the remaining three episodes it was introduced because of poor therapeutic

Olanzapine induced neuroleptic malignant

Olanzapine induced neuroleptic malignant syndrome—a case review

✍ Aleš Kogoj; Ingrid Velikonja 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders. Although potent neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs may also be a cause of NMS. Three databases were searched using the terms ‘